Search research articles
Contact Us
Filters
Showing results (121-130 of 179) with videos related to
Page
of 18
Sort By:
Clinical Colorectal Cancer
|
March 13, 2016
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
Hui-Li Wong, Belinda Lee, Kathryn Field, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem, Sanne Huijberts, Axel Grothey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Lavinia Tan, Ben Tran, Jeanne Tie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2021
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero, Axel Grothey, Eric Van Cutsem, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 2015
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
Nishi Kothari, Richard Kim, Robert N Jorissen, et al.
The Oncologist
|
July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J Wagner, William D Tap, Sebastian Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
NPJ Precision Oncology
|
September 9, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Subotheni Thavaneswaran, Frank Lin, John P Grady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer
Pradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
Molecular Diagnosis & Therapy
|
November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian Laboratory
Adel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 179) with videos related to
Sort By:
Page
of 18
Clinical Colorectal Cancer
|
March 13, 2016
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
Hui-Li Wong, Belinda Lee, Kathryn Field, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem, Sanne Huijberts, Axel Grothey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Lavinia Tan, Ben Tran, Jeanne Tie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2021
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero, Axel Grothey, Eric Van Cutsem, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 2015
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
Nishi Kothari, Richard Kim, Robert N Jorissen, et al.
The Oncologist
|
July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J Wagner, William D Tap, Sebastian Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
NPJ Precision Oncology
|
September 9, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Subotheni Thavaneswaran, Frank Lin, John P Grady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer
Pradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
Molecular Diagnosis & Therapy
|
November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian Laboratory
Adel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
Page
of 18